• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

lncRNA HOTAIR作为非小细胞肺癌检测和分期生物标志物的诊断价值

Diagnostic value of lncRNA HOTAIR as a biomarker for detecting and staging of non-small cell lung cancer.

作者信息

Yao Xin, Wang Teng, Sun Meng Yang, Yuming Yang, Guixin Duan, Liu Jing

机构信息

Medical College of Nantong University, Nantong, China.

Department of Bioinformatics, School of Basic Medical Sciences, Chongqing Medical University, Chongqing, China.

出版信息

Biomarkers. 2022 Sep;27(6):526-533. doi: 10.1080/1354750X.2022.2085799. Epub 2022 Aug 12.

DOI:10.1080/1354750X.2022.2085799
PMID:35959801
Abstract

Since the role of long non-coding RNA (lncRNA) HOTAIR is yet to be established in non-small cell lung cancer (NSCLC), we tried to explore the expression of lncRNA HOTAIR in NSCLC and evaluate the correlation between the combined detection of lncRNA HOTAIR and routine tumour markers and the pathological staging of lung cancer.This study prospectively included 148 patients with NSCLC selected from our hospital from January 2017 to September 2020 as the lung cancer group, and 148 healthy volunteers who referred for physical examination were selected as the control group. Fluorescence in situ hybridisation was used to detect the expression of lncRNA HOTAIR in the cancerous tissues and adjacent tissues of lung cancer patients; the immunofluorescence method was used to detect the serum NSE, CEA and CYFRA21-1 levels of the two groups of testers. Correlation analysis was used to evaluate any relation between cancer staging and markers. In addition, ROC curve analysis was used to estimate sensitivity, specificity, positive predictive value, and negative predictive value.The expression of lncRNA HOTAIR in lung cancer tissues was higher than control or surrounding tissue (<0.05). Also, high levels of NSE, CEA and CYFRA21-1 were observed in lung cancer group (<0.05). In both N and T stage, the expression of lncRNA HOTAIR combined with NSE, CEA and CYFRA21-1 levels increased with the increase in the number of stages (<0.05). The results of single factor analysis showed that NSE, CEA, CYFRA21-1 and lncRNA HOTAIR all have appropriate diagnostic value for detecting lung cancer (specificity of 92.6, 91.5, 90.6, 86.9%, respectively and the sensitivity of 61.3, 62.9, 55.4, 52.3%, respectively).LncRNA HOTAIR is a novel diagnostic test with high diagnostic value for detecting of pathological staging of NSCLC; however, the diagnostic accuracy of lncRNA HOTAIR is not higher than other tumour biomarkers.

摘要

由于长链非编码RNA(lncRNA)HOTAIR在非小细胞肺癌(NSCLC)中的作用尚未明确,我们试图探究lncRNA HOTAIR在NSCLC中的表达情况,并评估lncRNA HOTAIR与常规肿瘤标志物联合检测和肺癌病理分期之间的相关性。本研究前瞻性纳入了2017年1月至2020年9月期间我院收治的148例NSCLC患者作为肺癌组,选取148例因体检前来就诊的健康志愿者作为对照组。采用荧光原位杂交法检测肺癌患者癌组织及癌旁组织中lncRNA HOTAIR的表达;采用免疫荧光法检测两组检测者血清中的NSE、CEA和CYFRA21-1水平。采用相关性分析评估癌症分期与标志物之间的关系。此外,采用ROC曲线分析来估计敏感性、特异性、阳性预测值和阴性预测值。lncRNA HOTAIR在肺癌组织中的表达高于对照组或周围组织(<0.05)。此外,肺癌组中NSE、CEA和CYFRA21-1水平较高(<0.05)。在N期和T期,lncRNA HOTAIR联合NSE、CEA和CYFRA21-1水平均随着分期数的增加而升高(<0.05)。单因素分析结果显示,NSE、CEA、CYFRA21-1和lncRNA HOTAIR对肺癌检测均具有一定的诊断价值(特异性分别为92.6%、91.5%、90.6%、86.9%,敏感性分别为61.3%、62.9%、55.4%、52.3%)。lncRNA HOTAIR是一种对NSCLC病理分期检测具有较高诊断价值的新型诊断方法;然而,lncRNA HOTAIR的诊断准确性并不高于其他肿瘤生物标志物。

相似文献

1
Diagnostic value of lncRNA HOTAIR as a biomarker for detecting and staging of non-small cell lung cancer.lncRNA HOTAIR作为非小细胞肺癌检测和分期生物标志物的诊断价值
Biomarkers. 2022 Sep;27(6):526-533. doi: 10.1080/1354750X.2022.2085799. Epub 2022 Aug 12.
2
Diagnostic Value and Clinical Significance of Combined Detection of Serum Markers CYFRA21-1, SCC Ag, NSE, CEA and ProGRP in Non-Small Cell Lung Carcinoma.血清标志物CYFRA21-1、SCC Ag、NSE、CEA和ProGRP联合检测在非小细胞肺癌中的诊断价值及临床意义
Clin Lab. 2020 Nov 1;66(11). doi: 10.7754/Clin.Lab.2020.191243.
3
Thymidine kinase 1 combined with CEA, CYFRA21-1 and NSE improved its diagnostic value for lung cancer.胸苷激酶1联合癌胚抗原、细胞角蛋白19片段和神经元特异性烯醇化酶可提高其对肺癌的诊断价值。
Life Sci. 2018 Feb 1;194:1-6. doi: 10.1016/j.lfs.2017.12.020. Epub 2017 Dec 14.
4
Clinical Evaluation of Tumor Markers for Diagnosis in Patients with Non-small Cell Lung Cancer in China.中国非小细胞肺癌患者肿瘤标志物诊断的临床评估
Asian Pac J Cancer Prev. 2015;16(12):4891-4. doi: 10.7314/apjcp.2015.16.12.4891.
5
[Clinical value of tumor-associated autoantibodies in diagnosis of early non-small cell lung cancer].肿瘤相关自身抗体在早期非小细胞肺癌诊断中的临床价值
Zhonghua Yu Fang Yi Xue Za Zhi. 2021 Dec 6;55(12):1426-1434. doi: 10.3760/cma.j.cn112150-20210511-00461.
6
Circulating long noncoding RNA act as potential novel biomarkers for diagnosis and prognosis of non-small cell lung cancer.循环长非编码 RNA 作为非小细胞肺癌诊断和预后的潜在新型生物标志物。
Mol Oncol. 2018 May;12(5):648-658. doi: 10.1002/1878-0261.12188. Epub 2018 Mar 25.
7
[Diagnostic value of serum tumor markers CEA, CYFRA21-1, SCCAg, NSE and ProGRP for lung cancers of different pathological types].[血清肿瘤标志物癌胚抗原(CEA)、细胞角蛋白片段21-1(CYFRA21-1)、鳞状细胞癌抗原(SCCAg)、神经元特异性烯醇化酶(NSE)及胃泌素释放肽前体(ProGRP)对不同病理类型肺癌的诊断价值]
Nan Fang Yi Ke Da Xue Xue Bao. 2022 Jun 20;42(6):886-891. doi: 10.12122/j.issn.1673-4254.2022.06.12.
8
Circulating long non-coding RNA AFAP1-AS1 is a potential diagnostic biomarker for non-small cell lung cancer.循环长非编码 RNA AFAP1-AS1 是一种非小细胞肺癌的潜在诊断生物标志物。
Clin Chim Acta. 2017 Dec;475:152-156. doi: 10.1016/j.cca.2017.10.027. Epub 2017 Nov 6.
9
[Clinical value of combined detection of serum tumor markers in lung cancer diagnosis].血清肿瘤标志物联合检测在肺癌诊断中的临床价值
Sichuan Da Xue Xue Bao Yi Xue Ban. 2008 Sep;39(5):832-5.
10
Prediction of lung cancer based on serum biomarkers by gene expression programming methods.基于基因表达编程方法通过血清生物标志物预测肺癌
Asian Pac J Cancer Prev. 2014;15(21):9367-73. doi: 10.7314/apjcp.2014.15.21.9367.

引用本文的文献

1
The Regulatory Role of LncRNAs in Modulating Autophagy and Drug Resistance in Non-Small-Cell Lung Cancer: Focus on Targeted Therapeutic Approaches.长链非编码RNA在调节非小细胞肺癌自噬和耐药性中的调控作用:聚焦靶向治疗方法
Biomolecules. 2025 Jul 5;15(7):968. doi: 10.3390/biom15070968.
2
Diagnostic role of circulating long non-coding RNA LINC00312 in patients with non-small cell lung cancer: a retrospective study.循环长链非编码RNA LINC00312在非小细胞肺癌患者中的诊断作用:一项回顾性研究
BMC Cancer. 2025 Jan 9;25(1):47. doi: 10.1186/s12885-024-13393-1.
3
HOTAIR in cancer: diagnostic, prognostic, and therapeutic perspectives.
癌症中的HOTAIR:诊断、预后及治疗前景
Cancer Cell Int. 2024 Dec 19;24(1):415. doi: 10.1186/s12935-024-03612-x.
4
Comprehensive review of LncRNA-mediated therapeutic resistance in non-small cell lung cancer.非小细胞肺癌中长链非编码RNA介导的治疗耐药性综述
Cancer Cell Int. 2024 Nov 9;24(1):369. doi: 10.1186/s12935-024-03549-1.
5
Diagnostic Accuracy of Exosomal Long Noncoding RNAs in Diagnosis of NSCLC: A Meta-Analysis.外泌体长链非编码 RNA 诊断非小细胞肺癌的诊断准确性:一项荟萃分析。
Mol Diagn Ther. 2024 Jul;28(4):455-468. doi: 10.1007/s40291-024-00715-z. Epub 2024 Jun 5.
6
Prognostic significance of LINC01132 in lung cancer and its regulatory role in tumor progression.LINC01132在肺癌中的预后意义及其在肿瘤进展中的调控作用。
Discov Oncol. 2024 Feb 25;15(1):49. doi: 10.1007/s12672-024-00884-7.
7
Long noncoding RNA lnc-SNAPC5-3:4 inhibits malignancy by directly upregulating miR-224-3p in non-small cell lung cancer.长链非编码RNA lnc-SNAPC5-3:4通过直接上调非小细胞肺癌中的miR-224-3p抑制恶性肿瘤。
Heliyon. 2024 Jan 13;10(2):e24668. doi: 10.1016/j.heliyon.2024.e24668. eCollection 2024 Jan 30.
8
A concise review of the regulatory, diagnostic, and prognostic implications of HOXB-AS3 in tumors.HOXB-AS3在肿瘤中的调控、诊断及预后意义的简要综述
J Cancer. 2024 Jan 1;15(3):714-728. doi: 10.7150/jca.91033. eCollection 2024.
9
Establishment of a prognosis prediction model for lung squamous cell carcinoma related to PET/CT: basing on immunogenic cell death-related lncRNA.基于免疫原性细胞死亡相关长非编码 RNA 的肺鳞状细胞癌 PET/CT 预后预测模型的建立。
BMC Pulm Med. 2023 Dec 15;23(1):511. doi: 10.1186/s12890-023-02792-y.
10
Exploring the Potential of Non-Coding RNAs as Liquid Biopsy Biomarkers for Lung Cancer Screening: A Literature Review.探索非编码RNA作为肺癌筛查液体活检生物标志物的潜力:文献综述
Cancers (Basel). 2023 Sep 28;15(19):4774. doi: 10.3390/cancers15194774.